Healthcare | March 08, 2022
American Oncology Institute highlights spirit of women cancer survivors
AOI is the leading cancer hospital chain of South Asia operating 16 cancer hospitals in the region
AOI is the leading cancer hospital chain of South Asia operating 16 cancer hospitals in the region
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
A simple blood test detects over 30 types of cancers
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Subscribe To Our Newsletter & Stay Updated
